CDC新冠疫苗妊娠登记系统:设计、数据收集、应答率与队列描述
美国CDC建立新冠疫苗妊娠登记系统(C19VPR)以监测疫苗安全性,纳入妊娠期或末次月经前30天内接种新冠疫苗者,通过电话访谈和病历复核追踪参与者及婴儿健康结局。2021年1月至6月中旬识别123,609名潜在参与者,其中23,339名符合条件并入组,85.3%同意病历复核。
要点
- 2021年1月至6月中旬识别123,609名18-54岁潜在参与者,23,339名符合条件并入组。
- 入组者中85.3%同意本人和/或婴儿的病历复核,89.7%在妊娠结束前完成基础免疫系列。
- 参与者以非西班牙裔白人(79.1%)、城市居民(93.3%)为主,48.3%年龄在30-34岁。
核心结论
- 该登记系统持续为妊娠人群接种新冠疫苗的安全性提供重要信息,该人群感染新冠后不良结局风险较高且未纳入授权前临床试验。
- 从该登记系统汲取的经验可指导未来针对妊娠人群及其婴儿的疫苗安全监测工作的开发与实施。
研究设计与样本
- 美国疾病控制与预防中心(CDC)开发并实施CDC新冠疫苗妊娠登记系统(C19VPR),本文描述其方案。
- 潜在参与者为在妊娠期或妊娠相关末次月经前30天内接种新冠疫苗者,通过电话访谈和可用病历复核监测参与者及其婴儿的健康结局。
- 特定结局(包括出生缺陷)由临床医生审核,部分情况下使用病历确认并补充参与者报告的健康状况。
主要发现
- 2021年1月至2021年6月中旬识别出123,609名18-54岁潜在参与者,其中23,339名符合条件并入组。
- 入组参与者中85.3%同意对本人和/或婴儿进行病历复核。
- 参与者以非西班牙裔白人为主(79.1%),93.3%为城市地区居民,48.3%年龄在30至34岁之间。
- 大多数参与者在妊娠结束前完成基础免疫系列接种(89.7%)。
- 许多参与者为医务人员(44.8%),可能与疫苗接种规划的分阶段推广有关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The U.S. Centers for Disease Control and Prevention (CDC) developed and implemented the CDC COVID-19 Vaccine Pregnancy Registry (C19VPR) to monitor vaccine safety. Potential participants who received a COVID-19 vaccine in pregnancy or up to 30 days prior to their pregnancy-associated last menstrual period were eligible to participate in the registry, which monitored health outcomes of participants and their infants through phone interviews and review of available medical records. Data for select outcomes, including birth defects, were reviewed by clinicians. In certain cases, medical records were used to confirm and add detail to participant-reported health conditions. This paper serves as a description of CDC C19VPR protocol. We describe the development and implementation for each data collection aspect of the registry (i.e., participant phone interviews, clinical review, and medical record abstraction), data management, and strengths and limitations. We also describe the demographics and vaccinations received among eligible and enrolled participants. There were 123,609 potential participants 18-54 years of age identified from January 2021 through mid-June 2021; 23,339 were eligible and enrolled into the registry. Among these, 85.3 % consented to medical record review for themselves and/or their infants. Participants were majority non-Hispanic White (79.1 %), residents of urban areas (93.3 %), and 48.3 % were between 30 and 34 years of age. Most participants completed the primary series of vaccination by the end of pregnancy (89.7 %). Many participants were healthcare personnel (44.8 %), possibly due to the phased roll-out of the vaccination program. The registry continues to provide important information about the safety of COVID-19 vaccination among pregnant people, a population with higher risk of poor outcomes from COVID-19 who were not included in pre-authorization clinical trials. Lessons learned from the registry may guide development and implementation of future vaccine safety monitoring efforts for pregnant people and their infants.
引用
- Madni SA, Sharma AJ, Zauche LH, et al. CDC COVID-19 Vaccine Pregnancy Registry: Design, data collection, response rates, and cohort description. Vaccine. 2023. PMID: 38057207. doi:10.1016/j.vaccine.2023.11.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。